Potent immunosuppressive activity of a phosphodiesterase‐4 inhibitor N‐acylhydrazone in models of lipopolysaccharide‐induced shock and delayed‐type hypersensitivity reaction
Sign Up to like & getrecommendations! Published in 2018 at "International Immunopharmacology"
DOI: 10.1016/j.intimp.2018.09.047
Abstract: &NA; Immunosuppressive drugs are widely used for the treatment of immune‐mediated diseases and inflammation, but the toxicity and side effects of the available immunosuppressors make the search of new agents of great relevance. Here, we… read more here.
Keywords: lassbio; activity; phosphodiesterase; lassbio 1386 ... See more keywords
Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative
Sign Up to like & getrecommendations! Published in 2018 at "Pharmaceuticals"
DOI: 10.3390/ph11040119
Abstract: Pulmonary arterial hypertension (PAH) is a chronic cardiovascular disease that displays inflammatory components, which contributes to the difficulty of adequate treatment with the available therapeutic arsenal. In this context, the N-acylhydrazone derivative LASSBio-1359 was previously… read more here.
Keywords: design synthesis; lassbio; lassbio 1359; experimental theoretical ... See more keywords
Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15080913
Abstract: Combretastatin A-4 (CA-4, 1) is an antimicrotubule agent used as a prototype for the design of several synthetic analogues with anti-tubulin activity, such as LASSBio-1586 (2). A series of branched and unbranched homologs of the… read more here.
Keywords: putative dual; dual inhibitor; lassbio; inhibitor tubulin ... See more keywords
Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15041282
Abstract: LASSBio-1920 was synthesized due to the poor solubility of its natural precursor, combretastatin A4 (CA4). The cytotoxic potential of the compound against human colorectal cancer cells (HCT-116) and non-small cell lung cancer cells (PC-9) was… read more here.
Keywords: profile evaluation; evaluation novel; pharmacokinetic profile; lassbio 1920 ... See more keywords